Adjuvant Capital — 2023 Investments

3 investments dated 2023 · listed companies and verified rows first · show all

MinervaXminervax.com inSeries B · Oct 2023 · $58M✓ verified

MinervaX is a biotech company developing prophylactic vaccines, with therapeutic focus areas including immunology and infectious disease.

BiotechHealthtech

PerBengt(CSO)

Co-investorsIndustrifonden OrbiMed Pureos Bioventures Sanofi Ventures Sunstone Capital EQT Life Sciences +2 more

Antiva Biosciencesantivabio.com inApr 2023 · $53M

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in

Co-investorsAvestria Ventures Brace Pharma Canaan Partners Gaingels GV (Google Ventures)HBM Healthcare Investments +6 more

Codagenixcodagenix.com in 𝕏Series B · Feb 2023 · $20M

Codagenix develops viral vaccines and virotherapeutics using codon deoptimization, a method for engineering attenuated viruses.

BiotechDeep TechHealthtechFarmingdale, US

John Robert Coleman(Executive Officer, Director)Steffen Mueller(Co-Founder, President & Chief Scientific Officer)inCharlie Petty(Director)Steven Winick(Director)Jill Howe(Director)Paul Grint(Executive Chairman & Interim CEO)in

Co-investorsIn-Q-Tel Topspin Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.